Table 2.
Patient characteristics (effectiveness analysis set)
| Characteristic | Effectiveness analysis set (N = 670)a |
|---|---|
| Age, years | |
| Median (range) | 53 (15–75) |
| Mean ± SD | 49.64 ± 14.29 |
| Unknown | 11 (1.64) |
| Sex | |
| Male | 394 (58.81) |
| Female | 276 (41.19) |
| Number of transplants | |
| 1 | 554 (82.69) |
| ≥2 | 116 (17.31) |
| Unknown | 0 |
| Length of hospital stay after first transplantation, daysb | |
| Median (range) | 86.0 (21–482) |
| Mean ± SD | 102.8 ± 58.9 |
| Unknown | 25 (3.73) |
| Primary reason for HSCT | |
| Acute myeloid leukemia | 256 (38.21) |
| Acute lymphoblastic leukemia | 133 (19.85) |
| Myelodysplastic syndrome | 88 (13.13) |
| Lymphoid malignant tumor | 84 (12.54) |
| Other diseases | 109 (16.27) |
| CMV antibody combination | |
| R+/D+ | 222 (33.13) |
| R+/D− | 235 (35.07) |
| R−/D+ | 33 (4.93) |
| R−/D− | 29 (4.33) |
| Unknown | 151 (22.54) |
| Stem cell source | |
| Cord blood | 244 (36.42) |
| Bone marrow | 222 (33.13) |
| Peripheral blood | 204 (30.45) |
| Donor type | |
| Allogeneic transplantation | 670 (100.00) |
| Related | 188 (28.06) |
| Sibling | 113 (16.87) |
| Other sibling | 67 (10.00) |
| Unrelated | 482 (71.94) |
| Autologous transplantation | 0 |
| Unknown | 0 |
| HLA | |
| Matched | 204 (30.45) |
| Mismatched | 443 (66.12) |
| Mismatched excluding haploidentical | 359 (53.58) |
| Haploidentical | 84 (12.54) |
| Other | 0 |
| Unknown | 23 (3.43) |
| Conditioning regimen | |
| Myeloablative transplantation | 328 (48.96) |
| Anti-thymocyte globulin | 118 (17.61) |
| T-cell depletion or CD34(+) selected HSCT | 8 (1.19) |
| Pre-transplantation corticosteroid use | 310 (46.27) |
| GVHD prophylaxis | |
| Yes | 651 (97.16) |
| No | 1 (0.15) |
| Unknown | 18 (2.69) |
| Drugs used for GVHD prophylaxis (>5%)c | |
| Tacrolimus | 545 (81.34) |
| Methotrexate | 489 (72.99) |
| Mycophenolate mofetil | 135 (20.15) |
| Cyclosporine | 100 (14.93) |
| Cyclophosphamide | 47 (7.01) |
CMV cytomegalovirus, D donor, GVHD graft versus host disease, HSCT hematopoietic stem cell transplantation, HLA human leukocyte antigen, R recipient, SD standard deviation
aValues are n (%) of patients unless otherwise specified
bRelated to transplantation when receiving letermovir
cData based on multiple entries